Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56.

Pfizer stock is trading at a pivotal support level, indicating a promising long-term buying opportunity. Yet, beneath this challenging facade, Pfizer's narrative is woven with hope and strategic ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Our detailed analysis of Pfizer’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to the ...

Technical analysis shows bullish momentum for Pfizer's stock, with prices above key moving averages. Pfizer Inc. PFE has recently launched a multi-year cost reduction initiative aimed at saving ...

Related: Pfizer stock climbs on Q4 revenue and earnings ... represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...